# Signals Article on Putative Target P58340 for Acute Myeloid Leukemia
Background
The putative target P58340, also known as the protein encoded by the gene associated with acute myeloid leukemia (AML), presents a potential therapeutic avenue worth exploring. Preliminary data suggest that P58340 may play a role in the pathogenesis of AML, highlighting its relevance as a candidate for further investigation. Given the complexity of AML and the need for novel therapeutic strategies, P58340 warrants validation as a potential target for precision medicine approaches in this malignancy.Data-mining rationale
The rationale for investigating P58340 stems from a comprehensive data-mining effort that cross-referenced reviewed human entries from UniProt, specifically focusing on acute myeloid leukemia. This analysis utilized 671 microarray datasets available in the NCBI Gene Expression Omnibus (GEO), including GDS:200297053, GDS:200248681, GDS:200183844, GDS:200182030, and GDS:200067096. Notably, while P58340 appeared in expression-profiling studies, it lacks any registered Phase 1 or higher clinical programs, indicating a gap in its exploration as a therapeutic target.Why prior analyses may have missed this
Many of the GEO datasets utilized in this analysis predate the adoption of modern empirical-Bayes statistical methods, such as limma, which are crucial for accurate differential expression analysis. The absence of proper multiple-testing corrections in earlier studies may have led to the underappreciation of P58340's significance in AML. By re-analyzing these datasets with contemporary statistical techniques, we may uncover previously obscured insights into the role of P58340 in AML biology.Reasoning for further validation
To substantiate the potential of P58340 as a therapeutic target in AML, the following experimental approaches are suggested: 1. Re-analyze the matched GEO datasets using the limma package with a Benjamini-Hochberg false discovery rate (FDR) threshold of < 0.05 to identify differentially expressed genes with greater accuracy. 2. Validate the top differentially expressed genes associated with P58340 through quantitative PCR (qPCR) in an independent cohort of AML patients to confirm expression patterns. 3. Investigate tissue specificity of P58340 expression using resources such as the Genotype-Tissue Expression (GTEx) project and the Human Protein Atlas to assess its relevance in AML versus other tissues. 4. Utilize pathway analysis tools such as STRING and OmniPath to explore the biological pathways associated with P58340, providing context for its role in AML. 5. If validation is achieved, assess the druggability of P58340 through databases such as DGIdb and ChEMBL to evaluate its potential as a target for therapeutic intervention.References
- UniProt. P58340. [UniProt](https://www.uniprot.org/uniprot/P58340).
- NCBI GEO. GDS:200297053. [GEO](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200297053).
- NCBI GEO. GDS:200248681. [GEO](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200248681).
- NCBI GEO. GDS:200183844. [GEO](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200183844).
- NCBI GEO. GDS:200182030. [GEO](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200182030).
- NCBI GEO. GDS:200067096. [GEO](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200067096).